Vyant Bio, Inc. Common Stock
VYNT
VYNT was delisted on the 12th of May, 2023.
25 hedge funds and large institutions have $9.2M invested in Vyant Bio, Inc. Common Stock in 2017 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 8 increasing their positions, 7 reducing their positions, and 6 closing their positions.
14% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 7
10% more capital invested
Capital invested by funds: $8.36M → $9.2M (+$842K)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
4% less funds holding
Funds holding: 26 → 25 (-1)
17% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
+$4.54M |
| 2 |
PCM
Perkins Capital Management
Wayzata,
Minnesota
|
+$465K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$180K |
| 4 |
TSS
Two Sigma Securities
New York
|
+$135K |
| 5 |
Squarepoint
New York
|
+$49.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$317K |
| 2 |
Renaissance Technologies
New York
|
-$126K |
| 3 |
TDC
Thompson Davis & Co
Richmond,
Virginia
|
-$118K |
| 4 |
Bank of Montreal
Toronto,
Ontario, Canada
|
-$66K |
| 5 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$60.3K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
26
Bank of Montreal
Toronto,
Ontario, Canada
| – | -$66K | -161 | Closed |
|
27
PNC Financial Services Group
Pittsburgh,
Pennsylvania
| – | -$16K | -40 | Closed |
|
|
NFG
28
Next Financial Group
Houston,
Texas
| – | -$7K | -17 | Closed |
|
|
AG
29
Advisor Group
Phoenix,
Arizona
| – | -$5K | -13 | Closed |
|
|
TRCT
30
Tower Research Capital (TRC)
New York
| – | -$4K | -9 | Closed |
|
31
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | -$1.91K | -5 | Closed |
|
VYNT Hedge Fund Activity: Q4 2017 in Review
25 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Vyant Bio, Inc. Common Stock (VYNT) for Q4 2017, worth a combined $9.2M — up 10% from $8.36M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of VYNT and 5 opened new positions — a net loss of 1 holder — while 7 trimmed existing stakes and 8 added.
The largest buyer was Stonepine Capital Management, opening a new position worth an estimated $4.54M. The largest seller was UBS Group, cutting an estimated $317K.
- 25 institutional investors held Vyant Bio, Inc. Common Stock (VYNT) as of Q4 2017, down from 26 in Q3 2017.
- Funds reported $9.2M of Vyant Bio, Inc. Common Stock stock for Q4 2017, up 10% quarter-over-quarter.
- 5 funds opened new Vyant Bio, Inc. Common Stock positions in Q4 2017 and 6 closed out, a net change of -1 holder.
- The largest Vyant Bio, Inc. Common Stock buyer in Q4 2017 was Stonepine Capital Management, an estimated $4.54M added.
- The largest Vyant Bio, Inc. Common Stock seller in Q4 2017 was UBS Group, an estimated $317K sold.
Based on aggregated 13F filings for Q4 2017.